A new study called the NCI-MATCH trial that analyzes patients’ tumors to determine whether they contain gene abnormalities for which a targeted drug exists and assigns treatment based on the abnormality has gained popularity since its open enrollment in August 2015.
"Instead of thinking of a breast cancer treatment or a lung cancer treatment or colon, it looks at the different mutations that occur in the tumors," said lead author of the study, oncologist Robert Comis, in an NPR interview.
Researchers recruit people who have gone the traditional route of cancer treatments and failed. In its first three months, 800 patients who have an advanced solid tumor, lymphoma or myeloma have been enrolled.
In the NPR article, an advocate for patients talks about her involvement with the NCI-MATCH trial.
Read more here:
Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.